

- **CARRY** this card with you at all times.
- **CONTACT** your prescribing doctor if you experience any of the symptoms listed in this card.
- **GO TO** the hospital emergency room or call 911 if you cannot reach your prescribing doctor's office.
- **SHOW THIS CARD** to any healthcare provider involved in your care and if you go to the emergency room.

This material was developed by Amgen as part of the risk minimization plan for IMDELLTRA™. This material is not intended for promotional use.

FOR PATIENTS AND CAREGIVERS

Call your healthcare provider or get emergency help right away if you develop any of these signs and symptoms:

Symptoms of cytokine release syndrome (CRS)

- Fever (38 °C or higher)
- Chills
- Shortness of breath
- Confusion
- Restlessness
- Trouble breathing
- Fast or irregular heartbeat
- Palpitations
- Dizziness
- Headache
- Nausea
- Vomiting

- These are not all of the possible side effects you may have when taking IMDELLTRA. If you experience any side effects not listed here, tell your healthcare provider.

Symptoms of neurologic problems

- Trouble speaking or writing
- Memory loss
- Personality changes (encephalopathy)
- Confusion
- Feeling disoriented or having difficulty thinking clearly (delirium)
- Seizure
- Loss of balance or coordination (ataxia)
- Weakness or numbness of arms and legs
- Shakiness of your hands or limbs (tremor)
- Headache

- Tell your healthcare provider about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

Important to remember: Your healthcare provider will monitor you for 24 hours from the start of the infusion of the first two IMDELLTRA doses in an appropriate healthcare setting. Additionally, you should remain within one hour of an appropriate healthcare setting for an additional 24 hours, accompanied by a caregiver.

FOR HEALTHCARE PROVIDERS

IMPORTANT INFORMATION YOU SHOULD KNOW:

- IMDELLTRA is used for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
- IMDELLTRA has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information on IMDELLTRA, please refer to Health Canada's Notice of Compliance with conditions – drug products web site: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html>.

IMPORTANT INFORMATION YOU SHOULD KNOW (continued):

- IMDELLTRA can cause cytokine release syndrome (CRS) or neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or life-threatening.
- A CRS and ICANS management guide for healthcare professionals is available at www.amgen.ca/Imdelltra_HCP_AR_guide.pdf.
- Please consult the Product Monograph at www.amgen.ca/Imdelltra_PM_EN for important information on conditions of use, contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and administration.

**THIS PATIENT HAS
RECEIVED IMDELLTRA**

IMDELLTRA™
tarlatamab for injection

To be completed by the prescribing doctor:

Patient name: _____

Date and time of first IMDELLTRA infusion: _____

Healthcare provider name: _____

Office phone: _____

After-hours phone: _____